Sean Park­er finds a big role to play in can­cer R&D: The dis­rup­tive bil­lion­aire

In biotech, where every­thing is un­cer­tain, ex­ecs like to be as pre­dictable as pos­si­ble. Scripts are main­tained, nasty sur­pris­es are avoid­ed when­ev­er pos­si­ble and speed is fine, so long as you stick to your sched­ule and don’t look like you’re in too much of a hur­ry.

And then there’s Sean Park­er. Park­er had an easy role to play as the bil­lion­aire founder of a new can­cer R&D in­sti­tute. The trail­blaz­ers could get a fresh source of cash and a few years from now he could claim progress on the ever-pop­u­lar no­tion of find­ing a cure for can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.